A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey
Authors:
Abstract
Objective Despite the development of highly effective direct-acting antivirals, a prophylactic vaccine is needed for eradicating HCV. A major hurdle of HCV vaccine development is to induce immunity against HCV with high genome diversity. We previously demonstrated that a soluble E2 (sE2) expressed from insect cells induces broadly neutralising antibodies (NAbs) and prevents HCV infection. The objective of this study is to develop a multivalent HCV vaccine to increase the antigenic coverage. Design We designed a trivalent vaccine containing sE2 from genotype 1a, 1b and 3a. Mice and rhesus macaques were immunised with monovalent or trivalent sE2 vaccine, and sera or purified immunoglobulin were assessed for neutralisation against a panel of cell culture-derived virion (HCVcc) of genotype 1–7 in cell culture. Splenocytes from the vaccinated macaques were assessed for HCV-specific T cell response. Results We showed that the trivalent vaccine elicited pangenotypic NAbs in mice, which neutralised HCVcc of all the seven genotypes more potently than the monovalent vaccine. Further analyses demonstrated that each sE2 component of this trivalent vaccine elicited unique spectrum of NAbs which acted synergistically to inhibit HCV infection. Finally, the trivalent vaccine triggered stronger and more uniform multigenotypic neutralising antibody response than the monovalent vaccine in rhesus macaques. Conclusions In summary, we developed a trivalent HCV vaccine that induces broad and synergistic-acting neutralising antibodies in mice and non-human primates.Keywords
Funding Information
- Chinese National 973 Program
- National Natural Science Foundation of China
- CAS-SAFEA International Partnership Program for Creative Research Teams
This publication has 44 references indexed in Scilit:
- Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virusProceedings of the National Academy of Sciences, 2013
- Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 GlycoproteinJournal of Virology, 2013
- Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virusProceedings of the National Academy of Sciences, 2012
- Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsVaccine, 2010
- Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent ReinfectionGastroenterology, 2010
- Apolipoprotein C1 Association with Hepatitis C VirusJournal of Virology, 2008
- Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell CultureJournal of Virology, 2007
- Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzeesProceedings of the National Academy of Sciences, 2007
- Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV VirionsJournal of Virology, 2007
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimerasProceedings of the National Academy of Sciences, 2006